Canadian Markets close in 1 hr 18 mins

iCo Therapeutics Inc. (ICO.V)


TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.0450.000 (0.000%)
As of 12:33PM EDT. Market open.
People also watch
KNE.VDMA.VBTI.VATE.VEKG.V
Full screen
Previous Close0.045
Open0.045
Bid0.045 x
Ask0.050 x
Day's Range0.045 - 0.045
52 Week Range0.030 - 0.090
Volume194,181
Avg. Volume359,049
Market Cap3.8M
Beta3.71
PE Ratio (TTM)-3.75
EPS (TTM)-0.01
Earnings DateNov 26, 2015 - Nov 30, 2015
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
  • Newsfile20 days ago

    iCo Therapeutics Announces Election of Directors

    Vancouver, British Columbia--(Newsfile Corp. - June 30, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the election of directors at the annual meeting of shareholders held on June 29, 2017. At the annual meeting of shareholders held on June 29, 2017, Andrew Rae, Susan Koppy, Wiiliam Jarosz and Michael Liggett were elected directors of the Company and will hold office until the next annual general meeting ...

  • EQS Grouplast month

    iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset

    DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous15.06.2017 / 22:15 The issuer is solely responsible for the content of this announcement.

  • Newsfilelast month

    iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset

    Vancouver, British Columbia--(Newsfile Corp. - June 15, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported it will hold a pre IND meeting with the Division of Transplantation and Ophthalmology, US Food and Drug Administration (FDA) on June 21st, 2017. Discussions will focus on a proprietary dual action glaucoma asset with a novel mechanism of action that reduces intraocular pressure (IOP). The target is validated by literature and a ...